Company
Tonix Pharmaceuticals
NASDAQ:TNXP
Tonix is a biotechnology company where scientific breakthroughs begin with respecting the patients’ lived experiences. The company's pipeline responds to the call for solutions to complex, chronic and sometimes invisible conditions with scientific rigor, integrity, and purpose.
18 stories
Tonix Pharmaceuticals establishes niche as PTSD expert
The group is in the throes of developing an array of pharmaceutical products which take aim at neuropsychiatric conditions
Tonix Pharmaceuticals unveils pre-clinical results of small-pox vaccine TNX-801 at biothreats conference
A number of Cynomolgus Macaque, a type of monkey indigenous to Southeast Asia, were vaccinated with either high-dose or low-dose TNX-801
Archive
NA Proactive news snapshot: PowerOre, Black Iron, Helix Technologies, The Valens Company UPDATE ...
A glance at some of the day's highlights from the Proactive Investors US and Canada newswires
Tonix Pharmaceuticals completes fed-fasting, dose proportionality study for lead drug TNX-102 SL
The data is expected to satisfy pharmacokinetic requirements for NDAs for PTSD and fibromyalgia
Tonix cites initiation of Phase 3 trial for post-traumatic stress disorder drug
The clinical-stage biopharmaceutical company said enrollment began in March for the study of Tonmya for the treatment of post-traumatic stress disorder
Tonix Pharmaceuticals rallies after winning new European patent for TNX-601
The patent, which protects this new oral formulation of the antidepressant tianeptine, is set to last until April 2029
Tonix Pharmaceuticals stock nearly doubles after filing for upsized equity offering
Investors expect the proceeds to fund new late-stage study of lead drug candidate Tonmya for the treatment of PTSD
Tonix Pharmaceuticals shares rocket after FDA green-lights design of new late-stage study of Tonmya for PTSD
The clinical-stage biotech said it planned to start the RECOVERY trial for the treatment of PTSD in the first quarter of 2019
Small-Cap Snapshot: Tonix Pharmaceuticals wins FDA backing of Phase 3 trial for lead drug Tonmya
Esports Entertainment Group, Abercrombie & Fitch and Catalyst Pharmaceuticals Inc are also making news
Tonix Pharmaceuticals shares jump on favorable data related to PTSD drug
Based in New York City, Tonix is developing Tonmya, which has been granted a Breakthrough Therapy designation from the FDA, as a bedtime treatment for PTSD
Tonix Pharmaceuticals sees shares plummet after PTSD drug trial halted
Trials of its drug Tonmya, which treats military-related post-traumatic stress disorder, showed 'inadequate separation from placebo' after 12 weeks
Tonix Pharma shares halve after Phase 3 flop
The company was putting a brave face on the failure of the study, which was on the effect of its TNX-102 SL candidate on nerve pain
Tonix Pharmaceuticals Phase 2 trial success for military related PTSD
On the Nasdaq, the stock jumped around 20% in premarket deals to change hands at US$2.90.
Tonix shares tank after clinical trial provides a headache
Shares of Tonix Pharmaceuticals tank more than 35% after the company announces topline results of a clinical study of TNX-201 missed its primary efficacy endpoint for headache drug